血液疾患に伴う感染症に対するCefozopran (CZOP) の単独療法とAmikacin (AMK) 併用療法の有効性について

浦部 晶夫; 青木 克己; 北村 聖; 押味 和夫; 倉石 安庸; 戸川 敦; 藤田 彰; 小池 満; 大林 由明; 若林 芳久; 栗原 一郎; 星野 茂; 小澤 敬也; 東原 正明; 平井 久丸; 浅野 茂隆; 鈴木 憲史; 溝口 秀昭; 野中 泰延; 堀田 知光; 名越 温古; 小峰 光博; 西村 美樹; 別所 正美; 古沢 新平; 高久 史麿

doi:10.11553/antibiotics1968b.53.61

EFFICACY AND SAFETY OF CEFOZOPRAN (CZOP) MONOTHERAPY AND COMBINATION THERAPY WITH CZOP AND AMIKACIN (AMK) FOR INFECTIONS ACCOMPANYING HEMATOLOGICAL DISEASES

AKIO URABE, KATSUNORI AOKI, KIYOSHI KITAMURA, KAZUO OSHIMI, YASUNOBU KURAISHI, ATSUSHI TOGAWA, AKIRA FUJITA, MITSURU KOIKE, YOSHIAKI OHBAYASHI, YOSHIHISA WAKABAYASHI, ICHIRO KURIHARA, SHIGERU HOSHINO, KEIYA OZAWA, MASAAKI HIGASHIHARA, HISAMARU HIRAI, SHIGETAKA ASANO, KENSHI SUZUKI, HIDEAKI MIZOGUCHI, YASUNOBU NONAKA, TOMOMITSU HOTTA, HARUHISA NAGOSHI, MITSUHIRO OMINE, MIKI NISHIMURA, MASAMI BESSHO, SHINPEI FURUSAWA, FUMIMARO TAKAKU

Author information

AKIO URABE
Division of Hematology, NTT Kanto Medical Center
KATSUNORI AOKI
Department of Hematology,(Internal Medicine) Faculty of Medicine
KIYOSHI KITAMURA
Department of Laboratory Medicine, Faculty of Medicine, University of Tokyo
KAZUO OSHIMI
Department of Hematology, Juntendo University School of Medicine
YASUNOBU KURAISHI
Department of Internal Medicine 3, The Jikei University School of Medicine, School of Medicine
ATSUSHI TOGAWA
Department of Hematology, International Medical Center of Japan
AKIRA FUJITA
Department of Hematology, Showa General Hospital
MITSURU KOIKE
Department of Hematology/Oncology, St. Marianna University School of Medicine
YOSHIAKI OHBAYASHI
Department of Internal Medicine, Hatano Red Cross Hospital
YOSHIHISA WAKABAYASHI
Department of Internal Medicine, Yokohama Rosai Hospital
ICHIRO KURIHARA
Department of Internal Medicine, Koshigaya Hospital, Dokkyou University School of Medicine
SHIGERU HOSHINO
Department of Internal Medicine, Omiya Red Cross Hospital
KEIYA OZAWA
Department of Hematology, Jichi Medical School
MASAAKI HIGASHIHARA
Department of Internal Medicine, Kitasato University School of Medicine
HISAMARU HIRAI
Department of Cell Therapy & Transplantation Medicine, University of Tokyo Hospital, Kitasato University of Tokyo
SHIGETAKA ASANO
The Institute of Medical Science, University of Tokyo
KENSHI SUZUKI
Division of Hematology, Japanese Red cross Medical Center
HIDEAKI MIZOGUCHI
Department of Hematology, Tokyo Women's Medical University
YASUNOBU NONAKA
Department of Internal Medicine, Tokyo Metropolitan Police Hospital
TOMOMITSU HOTTA
Division of Hematology and Rheumatology, The Department of Internal medicine, Tokai University School of Medicine
HARUHISA NAGOSHI
Department of Hemato-oncology, Yokohama city Seibu Hospital, St. Marianna University School of Medicine
MITSUHIRO OMINE
Division of Hematology, Showa University Fujigaoka Hospital
MIKI NISHIMURA
The Second Department of Internal Medicine, Chiba University School of Medicine
MASAMI BESSHO
The First Department of Internal Medicine, Saitama Medical School
SHINPEI FURUSAWA
Department of Hematology, Dokkyou University School of Medicine
FUMIMARO TAKAKU
Jichi Medical School

JOURNAL FREE ACCESS

2000 Volume 53 Issue 2 Pages 61-74

DOI https://doi.org/10.11553/antibiotics1968b.53.61

Details

Abstract

We evaluated efficacy and safety of monotherapy with CZOP (1-2g×2/day) and combination therapy with CZOP (1-2g×2/day) and AMK (200mg×2/day) for infections in patients with hematological diseases. Efficacy was evaluated in 71 patients of monotherapy group and 70 patients of combination therapy group. Underlying diseases were mostly leukemia and lymphoma. Infections included sepsis, suspected sepsis, pneumonia and so on.
Efficacy in CZOP monotherapy was excellent in 21 patients (31.3%), good in 23 patients (34.3%), fair in 5 patients (7.5%) and the efficacy rate was 65.7%. On the other hand, in combination therapy, each was 14 patients (21.2%), 23 patients (34.8%), 12 patients (18.2%) and the efficacy rate was 56.1%.
Side effects such as eruption were noted in 2 patients. Abnormal laboratory findings were noted in 9 patients. All side effects as well as abnormal laboratory findings were minimal.
It was concluded that CZOP monotherapy was effective in the treatment of various infections accompanying hematological diseases.

Corresponding author

Register with J-STAGE for free!